Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus. Anti-Infectives, Drug Discovery, Antibiotics, and Microbiology

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Customized phage therapies to eradicate harmful bacteria in chronic diseases BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. Microbiome, Biotechnology, Drug Discovery, Phage Therapies, and Pharma

108 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

161 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Tackling bacterial infections, antimicrobial resistance, and their consequences in acute care settings. AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 by three highly renowned life sciences innovation companies, Boehringer Ingelheim, Evotec and bioMérieux, to become a global leader in the fight against bacterial infections, Antimicrobial Resistance (AMR) and their consequences in acute hospital settings. AUROBAC’s R&D strategy addresses these unmet medical needs with patient- and pathogen-targeted programs designed to tackle both the causes and consequences of potentially life-threatening bacterial infections and AMR, including hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) and sepsis.

14 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Molecular biology thought for your needs Biomnigene, a bioanalysis service company, helps prevent potential diseases and to authenticate, trace, secure, validate products and their effects through genetic analysis. Thanks to our expertise, we offer you integrated services for environmental, industrial (pharmaceutical, agro-food, cosmetic) or medical issues such as: - Analysis of the intestinal, skin, vaginal, pulmonary and soil microbiome (16S/ITS metagenomic, shotgun metagenomic, transcriptomic, WGS...). - Identification, quantification and authentication, monitoring of species in a pure sample and in a mixture (microorganisms, viruses, bacteria, meat, fish). - Genotyping - Antibody sequencing and safeguarding of hybridoma lines of special interest; - …

86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiome field. Da Volterra is a clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiota field. Our mission is to discover, develop and bring to market safe and novel therapeutic options, preserving patients’ microbiota to prevent and cure life-threatening diseases. We strive to serve patients by transforming the promise of science into innovative treatments which have the power to improve health and save lives.​ Committed to innovation, Da Volterra develops products intended to protect the intestinal …

36 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A nature-inspired solution to trap pathogens @AIS Biotech (with AIS for Anti Infective Sugar) is a French Biotech company based in the @Région Auvergne-Rhône-Alpes, France, incorporated in March 2023 with the objective of developing a new class of sugar-based anti-infective biotherapeutics to fight (re)emerging infectious diseases. Thanks to a Bioengineering plateform based on the expertise of the leading edge academic laboratory @CERMAV (@CNRS, @UGA, Grenoble, France), AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat infections by mimicking the natural host surface oligosaccharide binding-sites of pathogens. GlycoFlu, our first drug-candidate validated at the …

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing Tomorrow's Antibacterials Antabio is a privately-held clinical-stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments for drug-resistant infections due to CDC and WHO critical priority pathogens. Please visit www.antabio.com and follow us on Twitter @antabio Antibacterial drug discovery, Drug development, and Antibiotic Adjuvant

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading biotech in the development of innovative microbiome-based biotherapies YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs. Microbiome, Obesity, Gut modulator, Cardiometabolism, Cardiometabolic diseases, Microbiota, and Gut microbiota

200 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Natural molecule discovery, industrialized Natural products have contributed more than 500 molecules to pharmaceuticals. However, conventional methods for discovering new natural products are increasingly ineffective. Generare has developed a revolutionary platform that identifies and expresses a wide range of naturally occurring secondary metabolites, selected by millions of years of bacterial evolution. This platform allows us to reintroduce these lead molecules into clinical pipelines, reopening a validated avenue for therapeutic innovation. genomics, synbio, and microbiology

100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Diotheris develops anti-infective microbes to prevent bacterial infections and act against antibiotic resistance We create bacterial therapies of the human skin and mucosal microbiome against pathogenic bacteria. Our first suite of products (NASOFLORE line) targets Staphyloccocus aureus / MRSA (Methicillin resistant S aureus). The products based on live bacteria identified in our clinical and in vitro studies do not generate emergence of antibiotic resistance. antimicrobial, nose microbiome, therapeutics, LBP, Staphylococcus Aureus, and MRSA

10 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

CRO specialized in pharmaceutical drugability for research Expertise in Human and Animal health solid form characterization and formulation development. We deliver both experimental support and consulting services to biotechnology and pharmaceutical companies, not-for-profit organizations and complementary CROs. We are member of the association AFSSI, 1st French research center in Life Sciences, as a founding member and member of the board of Directors. Since March 2019 Joel Vacus, Drugabilis CEO & CSO, is vice-President of AFSSI. https://www.afssi.fr/ Feel free to contact us in order to exchange about your preclinical drug development! contact@drugabilis.com Lead optimization, Formulation, and Physical form optimization

66 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

OneHealth/AI DeepTech discovering patentable mixes of natural ingredients preserving health and optimizing bioprecesses Alphanosos, a Green One-Health DeepTech company, uses its own Artificial Intelligence algorithms to discover, develop and market active ingredients and products based on blends of extracts from non-pharmaceutical ingredients, in particular edible plants. These active mixtures, some of which are already patented in 15 countries for their antimicrobial activities, are intended for the animal hygiene, dermocosmetics, food preservation and cosmetics sectors, bioprocess optimization and in the longer term, for functional foods and disease treatments. The company began its Research and Development (R&D) activities in mid-2015 and is …

111 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Microbiology assays at previously impossible speeds and strain banks with amazing diversity ! Microbiology is what we do. Our unrelenting focus has enabled us to develop unique capabilities in ultra-high-throughput single-cell culture of microorganisms. Businesses in areas as diverse as pharma, agriculture, food, human health and environmental protection have partnered with us to gain powerful competitive advantages from our technology.So could yours. Our proprietary microfluidic platform is capable of : - identifying microbes of interest based on their functional characteristics among millions of candidates - perform a wide range of assays at previously impossible speeds - generate strain banks with …

90 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Vital new drugs for pandemic infections We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections. Pharmaceuticals, R&D, Antimicrobial Resistance, and Development

110 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

From Microbes to One Health. Taylor made R&D to tackle infectious diseases. Vibiosphen is a SME healthcare biotechnology in infectious diseases founded in 2014. Given the important and interdependent human, animal, and environmental dimensions of antimicrobial resistance, the One Health concept promotes a global effort to achieve the best health for people, animals, and the environment. In this context, Vibiosphen takes part of the efforts that are underway to develop new anti-infective therapies, to rejuvenate the antibiotic pipeline, develop novel antibiotics, and discover innovative therapeutic strategies for priority pathogens. Based on its pluridisciplinary and integrated approaches, Vibiosphen, with more than …

Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Founded in 1951 by pharmacists and microbiologists, biose® has 60-year experience in drug based on live bacteria, giving us a deep understanding of the entire process from discovery to commercialization. Focused on Health through microbiota and microbiome science, we use our skills for the discovery, product development, clinical studies and manufacturing of Live Biotherapeutic Products (LBPs). Our company is drug-GMP certified for the manufacturing of bacteria-based APIs, clinical and commercial products. Microbiome Therapeutics, live biotherapeutics, LBPs, and CDMO

117 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Investing dark biodiversity DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the microbial dark matter. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE (antibiotics, antifungals, antivirals and antiparasitics) target superbugs (microbes that resist to one or several antimicrobials) that cause life-threatening infections which are now spreading at high speed. This breakthrough approach gave birth to one of the World first specialized micro-biotechnology platforms and a unique collection …

Type: SMB Activities: biotech deeptech

Life-Transforming Medicines for Patients Living with Serious Rare Diseases VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. The company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in R&D, commercialization and …

104 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Subsidiary of BioNTech SE, now trading as BioNTech R&D (Austria). Developing novel anti-bacterials. BioNTech R&D Austria GmbH (formerly: PhagoMed Biopharma GmbH) is a fully owned subsidiary of BioNTech. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial infections. Biotech

56 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Leading the Microbiome revolution Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWSTTM, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in …

47 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leadership in overcoming the antibiotic resistance crisis. BioVersys AG is a SIX listed (BIOV) clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s two in house technology platforms: i) TRIC and ii)Ansamycin chemistry, BioVersys develops novel, innovative antibacterial drugs, overcoming resistance and modulating the microbiome. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial …

42 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redefining microbiome-based therapeutics MRM Health NV is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.The company is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent, Belgium, and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB and has a corporate collaboration with DuPont Nutrition …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better technology for better health LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK. vaccines, research & development, biotechnology, and antimicrobial resistance

147 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

196 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Precision Protein Antibiotics Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

144 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

438 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Evolution. Adaptation. Future. Phage-based solutions to combat bacteria. - Prevention - Diagnosis - Treatment "One Health" personalized treatments. biotecnología, microbiología, investigación, biomedicina, bacteria, phage, and phage therapy

133 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

The best Partner to elevate your Business in Health & Personal Care market Complife is a worldwide group, which provides consulting and testing services for cosmetics, food supplements, medical devices, biocides, household products and pharma. Our scientific experts will help you in demonstrating the safety, tolerability and efficacy of products, as well as their chemical and microbiological features. We offer a wide range of analysis and services in the field of microbiology, chemistry, product development, as well as in the regulatory sector, helping you to meet end users’ expectations. Regulatory & Consulting, Pre-clinical studies: in vitro, Analytical chemistry, Microbiology, and …

156 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics. Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform.

96 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Saving lives through affordable and efficient bacterial vaccines Our vision is to save lives with affordable and efficient vaccines against bacterial infections. At the core of our work is a platform technology that enables us to develop innovative bacterial vaccines with broad protection and high efficacy. This technology has the potential to significantly reduce or eliminate the need for antimicrobials.

Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

107 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vaccines against antibiotic-resistant infections Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators in the development of multi-pathogen vaccines for preventing antibiotics-resistant infections in all regions of the world. Our vaccines target high-risk populations, population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates. We are strongly committed to contribute to reducing antibiotic use in the world by following a One-Health approach. Vaxdyn is the first Spanish biotech funded by CARB-X. CARB-X awarded Vaxdyn …

21 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Aseptix Health Sciences is a global leader in next generation antimicrobials, specializing in novel and patented infection prevention products and technologies for medical, professional and consumer use. Aseptix’ sustainable antimicrobial technologies enable products to safely, effectively and quickly kill contagious pathogens and are used in a wide range of applications, industries and therapeutic areas. The Company markets its products and technologies through a combination of Aseptix branded and third party branded products, and licenses on its portfolio of patented technologies to global industry leaders in their markets. The corporate mission is to become the global alternative for user unsafe and …

65 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Focusing on Resistance in Antibiotic Development Qpex Biopharma, Inc. a Shionogi Group Company, is a resistance-focused infectious disease company on a mission to make both a dramatic and sustainable improvement in patient care. Leveraging a multi-faceted approach and a deep understanding of drug resistance mechanisms, we are creating novel products and development. strategies that overcome multi-drug resistance. We are advancing a robust portfolio of treatments that will bring innovation to antibiotic development and deliver the right treatments to the right patients in the right settings. During the previous decade, our team brought 4 antibiotic products to regulatory approvals, with an …

12 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The world's go-to partners for infectious disease biomaterials and testing services. We are the world’s leading experts and go-to collaborators in biological products and services, focused on protecting the health and safety of people around the world. For over 50 years, we have been partnering with healthcare and life science laboratories, manufacturers and suppliers across the globe to co-create and provide biological control materials, assay services and consulting for microbiology, molecular diagnostics and virology. Headquartered in Saint Cloud, Minnesota, we have additional facilities in California, Kentucky and Michigan. Microbiology, Biotechnology, Quality Control, Molecular Microbiology, Contract Research Organization, Virology, Anti-Infective Drug …

175 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without personal liability. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections …

76 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

A new way to tackle antimicrobial resistance Santero Therapeutics is developing an innovative approach to combating antimicrobial resistance (AMR), and antibiotic resistance in particular. The company wants to improve global health by developing innovative and safe antibiotics to eradicate multidrug-resistant deadly pathogens This field of research is one of the world's major public health challenges, as antimicrobial resistance (AMR) is one of the top ten threats to humanity, according to the United Nations. The number of deaths associated with AMR is estimated to be around 5 million per year worldwide in 2020, a figure that could double by 2050, and …

12 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing novel multi-targeted antibiotics with extraordinary potency against multi-drug resistant bacteria. smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

27 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative drug substances Aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients.

380 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people. Drug Discovery, Molecule characterization, Drug repurposing, and Novel compound applications

290 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Mastering the microbiome, transforming lives® EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.

201 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

540 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Precision Drugs against Eucaryotic Pathogens ASTRA Therapeutics is a Drug Discovery company with a mission to design and develop novel, precision engineered drugs against a whole range of Eukaryotic Pathogens.

505 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering the development of microbiome-based therapies using proprietary tools for their design and production. PharmaBiome is a privately-held spin-off company of ETH Zurich and a pioneer in the production of live biotherapeutic products to address disturbances of the gut microbiome. It has developed the first-in-the-industry, patent-protected technology platform for the production of standardized microbiome-based products. Founded in Zurich in 2015, at the intersection of microbiology, biotechnology, and data science, PharmaBiome believes that the future of microbiome-based therapeutics lies in developing the biotechnology needed to produce a solution compatible with the safety, efficiency, and trial requirements of any human medicine. This …

45 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Committed to protecting the world against dangerous and difficult-to-treat fungal pathogens At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Antifungals, Drug Development, Biotech, Infectious Disease, and …

65 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

we develop for patients Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university …

79 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Our expertise, Your discovery Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas. Based at Colwick Quays Business Park, Nottingham UK, our experienced scientific team offers bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Multiplex Immunoassay, Target and biomarker validation, In vitro functional assays, Molecular Biology, Receptor binding, Toxicity testing, Immuno-Oncology, Oncology, Immunology, Inflammation, and Respiratory

376 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Access. Better Lives. Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars. Biopharmaceuticals, Research and Development, Biosimilars, Biotechnology, Pharmaceutical, Biogenerics, Health, Cell Line Development, Business Development, and Regulatory

232 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

BioProcess InternationalTM is a monthly, controlled-circulation magazine devoted to the development, scale-up, and manufacture of biotherapeutics and biodiagnostics. Each issue provides the global industrial biotherapeutic community with up-to-date, peer-reviewed information detailing the business, politics, ethics, applications, products, and services required to successfully drive biopharmaceuticals, vaccines, and biodiagnostics through the development and manufacturing process. BPI is a business unit of Informa Connect https://informaconnect.com marketing, Biopharmaceutical, biotechnology, print, electronic, online, advertising programs, bioprocessing, vaccines, monoclonal antibodies, protein therapeutics, cell therapies, gene therapy, cell therapy, and biomanufacturing

181 similar entities Type: SMB Activities: biotech deeptech martech Technologies: Synthetic Biology

Through conferences, community and market insights, we create partnerships that help advance the next pillar of medicine Phacilitate creates an environment where promising innovation can turn into the products that are changing the future of medicine. Recognised as the market leader in providing the life science sector with strategic insight, inspiration and unparalleled business networking, Phacilitate enables professionals to stay abreast of the issues driving life science innovation. #advancedtherapies #biotech #celltherapy #genetherapy Clinical Development, Cell Therapy, Gene Therapy, Oncology, Cancer, Precision Medicine, Biotech, Advanced Therapy, Biotechnology, and Life Sciences

196 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Discovering & developing novel anti-infectives to treat multi-drug resistant bacterial & hard-to-treat viral infections. Venatorx Pharmaceuticals is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. antibiotics, antiinfectives, antivirals, drug development, drug discovery, pharmaceuticals, #battlesuperbugs, #WorkingToFightAMR, clinical, research, #squashsuperbugs, biotech, and antimicrobialresistance

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class solutions for unmet health and personal care needs Results through innovation. We are an innovative biotechnology group with two divisions. Our consumer health arm has commercial products for the personal care market addressing nail, skin, scalp and hair issues. NovaBiotics pharma division has advanced clinical-stage product candidates for medically unmet, life-limiting inflammatory, infectious and respiratory disease. Our highly disruptive solutions to personal care and health needs address significant global markets. biotechnology, biologics, infectious disease, and drug discovery & development

155 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Phico Therapeutics is a biotechnology company advancing the war on antibiotic resistance with engineered phage therapy. At Phico, we are developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”. Our patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. With a number of advantages over conventional antibiotic classes, SASPjectTM could form the basis for a new generation of antibiotics to overcome antimicrobial resistance. Watch our animation to discover how our technology works: https://www.youtube.com/channel/UCjPndK0F9ufmEy9fBQFTsUg Twitter: @Phicotx …

16 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Locus Biosciences, Inc. is a biotechnology company that develops precision, engineered bacteriophage products. Locus Biosciences is a clinical-stage biotechnology company developing engineered bacteriophage products to address critical unmet medical needs in bacterial infections and immunology. The LOCUS platform combines predictive artificial intelligence and automated robotics to deliver optimized precision phage therapies that specifically kill target pathogens while leaving non-target bacteria (i.e., the rest of the patient’s microbiome) unaffected. Locus has strong backing from partners, having signed contracts with BARDA and CARB-X. The company recently completed the open-label portion of a Phase 2 trial assessing LBP-EC01 for the treatment of uncomplicated …

35 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

543 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

At Bioharmony Therapeutics, we are developing nontraditional antimicrobial therapeutics by exploiting millions of years of phage-bacteria evolution. Our focus is on targeting infectious diseases caused by multidrug-resistant (MDR) Gram-negative bacteria. Our primary therapeutic indication is for Acinetobacter baumannii skin and wound infections.

53 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mission We harness the power of molecular microbiology to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care to guide antibiotic therapy selection and help improve antibiotic stewardship. About Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics to help combat infectious disease. Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels to address the global threat of antimicrobial resistance (AMR), improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). Together we improve patient …

25 similar entities Type: SMB Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy

106 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

BIONEEDS INDIA PRIVATE LIMITED is a Bangalore based Contract Research Organization providing Integrated Discovery, Development and Regulatory Services to Pharmaceutical, Biopharmaceutical, Agrochemical, Industrial chemical, Herbal/Nutraceutical and Medical device companies. Accreditation/Certifications • National GLP Compliance Monitoring Authority (NGCMA), Dept. of Science and Technology, Government of India • Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment, Forests and Climate Change, GOI. • State Drug Controller as a Government approved Drug Testing Laboratory for carrying out tests on Drugs / Cosmetics and • Raw Materials used in their manufacture on behalf of licensees for manufacture …

109 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We develop oral small-molecule and protein therapeutics to treat hereditary angioedema (HAE) and other rare diseases. BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices …

151 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology